BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
Clinical - Phase III
Alcobra (ADHD) Announces Completion Of All Patient Visits In Phase 3 Clinical Trial Of MDX In Adult ADHD 9/22/2014
CytRx Corporation (CYTR) Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas And Global Phase 2b Small Cell Lung Cancer Trial Designs At ESMO 2014 Congress 9/22/2014
Tenax Therapeutics Announces First Patients Enrolled In Phase 3 LEVO-CTS Clinical Trial Of Levosimendan 9/22/2014
Elusys Therapeutics, Inc. Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 9/22/2014
Threshold Pharmaceuticals, Inc. (THLD) Announces Its Phase 3 Trial Of TH-302 In Patients With Advanced Soft Tissue Sarcoma Will Continue As Planned Following Protocol-Specified Interim Analysis 9/22/2014
TauRx Therapeutics Achieves Enrollment Target For Second Phase 3 Clinical Trial Of LMTX™ In Alzheimer's Disease 9/22/2014
Boston Therapeutics, Inc. Signs Clinical Trial Agreement With Prestigious Joslin Diabetes Center For Phase III Study Of BTI-320 9/22/2014
Dynavax Technologies Corporation (DVAX) Completes Enrollment Of Phase 3 Study Of HEPLISAV-B™ 9/22/2014
BioSpecifics Technologies Corporation (BSTC) Announces New MULTICORD And Retreatment Data For XIAFLEX® For Dupuytren's Contracture Presented At American Society For Surgery Of The Hand Annual Meeting 9/19/2014
BioTime (BTX) Announces Presentation Of Phase 3 Data At EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 9/19/2014
Transparency Life Sciences To Conduct Sarcoidosis Trial For Auven Therapeutics (previously known as Celtic Therapeutics Management L.L.L.P.) ' Kiacta™ Using Crowdsourcing And Telemonitoring 9/19/2014
Regeneron Pharmaceuticals, Inc. (REGN) Wins Breakthrough Therapy Designation From FDA For EYLEA 9/18/2014
Novo Nordisk A/S (NVO)'s Diabetes Drug Ryzodeg Effective In Phase 3b Study 9/18/2014
Enrollment In Argos Therapeutics, Inc. (ARGS)' Pivotal Phase 3 ADAPT Trial Of AGS-003 For Metastatic Renal Cell Carcinoma Surpasses Fifty Percent 9/18/2014
Eli Lilly and Company (LLY) Release: CYRAMZA™ In Combination With Paclitaxel Significantly Improves Overall Survival In Second-Line Gastric Cancer Patients 9/18/2014
Synergy Pharmaceuticals Reaches Halfway Mark For Second Pivotal Phase 3 Trial Of Plecanatide In Patients With Chronic Idiopathic Constipation 9/18/2014
Merck & Co. (MRK)'s Long-Delayed Osteoporosis Drug Passes Trial 9/17/2014
ImmunoCellular Therapeutics, Ltd (IMUC) Receives Positive Regulatory Feedback On ICT-107 Supporting Advancement To Registrational Phase 3 Testing In Newly Diagnosed Glioblastoma 9/17/2014
Achaogen (AKAO) Announces First Patient Enrollment In A Phase 3 Clinical Trial Of Plazomicin To Treat Infections Caused By Carbapenem-Resistant Enterobacteriaceae (CRE) 9/17/2014
Intarcia Therapeutics, Inc. Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 9/17/2014
Soligenix (SNGX) Announces FDA Clearance Of Phase 3 Clinical Protocol Of SGX301 In Cutaneous T-Cell Lymphoma 9/17/2014
Merck & Co. (MRK) Presents First Phase 3 Data In Japanese Patients For Omarigliptin, An Investigational Once-Weekly DPP-4 Inhibitor For Type 2 Diabetes 9/17/2014
Janssen-Cilag International NV (JNJ) Release: Analysis Of Pooled Data From Phase 3 Trial Results Show Glycaemic Efficacy Of INVOKANA® (Canagliflozin) Is Largely Independent Of Beta-Cell Function And Insulin Sensitivity In The Treatment Of Type 2 Diabetes In Adults 9/17/2014
Isis Pharmaceuticals, Inc. (ISIS) Earns $4 Million From Achaogen (AKAO) For The Initiation Of A Phase 3 Study Of Plazomicin 9/17/2014
Analyst: Safety Worries Dog Merck & Co. (MRK)’s Osteoporosis Drug 9/16/2014
Amgen (AMGN) Announces Results From Several New Exploratory Analyses Evaluating Long-Term Impact Of Treatment With Prolia® (Denosumab) In Postmenopausal Women With Osteoporosis 9/16/2014
Bayer HealthCare Pharmaceuticals (BAYA.F) And Orion Corporation Initiate Phase 3 Trial Of ODM-201 In Men With High-Risk Non-Metastatic Castration-Resistant Prostate Cancer 9/16/2014
OncoGenex Pharmaceuticals Inc. (OGXI) Announces Completion Of Patient Enrollment In The Phase 3 AFFINITY Trial Of Custirsen In Combination With Cabazitaxel/Prednisone As Second-Line Chemotherapy In Men With Metastatic Castrate-Resistant Prostate Cancer 9/16/2014
CSL Behring Announces Last Patient Treated In Phase 3 Study Of Fibrinogen Concentrate To Control Bleeding During Aortic Aneurysm Surgery 9/16/2014
Boehringer Ingelheim Corporation Release: Type 2 Diabetes: Investigational Empagliflozin/Linagliptin Combination Tablet Shows Sustained Reduction In Blood Glucose In Phase 3 Study 9/16/2014
Agile Therapeutics, Inc. Initiates Phase 3 SECURE Study For Twirla™ 9/16/2014
ZS Pharma (ZSPH) Presents New Data From ZS003 A Two Week Phase 3 Trial Demonstrating That ZS-9 Prevented Recurrence Of Hyperkalemia In Heart Failure Patients On RAASi 9/16/2014
Relypsa, Inc. (RLYP) Announces New Analysis Of Phase 3 Data Demonstrating Patiromer's Ability To Rapidly Correct, And Prevent Recurrence Of, Hyperkalemia In Heart Failure And Non-Heart Failure Patients 9/16/2014
Mylan Inc. (MYL) Commences Phase 3 Clinical Trials For Its Generic Version Of Advair Diskus® And Insulin Analog To Lantus® 9/16/2014
Roche (RHHBY) Starts Pivotal Late-Stage Trial For Eye Drug Lampalizumab 9/15/2014
Cardio3 BioSciences Receives Approval For The Continuation Of Its Chart-1 Phase III Clinical Trial From The DSMB 9/15/2014
Amgen (AMGN) Presents Analyses Of Phase 3 Ivabradine Data For The Treatment Of Chronic Heart Failure 9/15/2014
TG Therapeutics, Inc. (MHA) Announces Special Protocol Assessment (SPA) Agreement With The FDA For Its First Phase 3 Clinical Trial Of TG-1101 (Ublituximab) In Combination With Imbruvica(R) (Ibrutinib) For Patients With Previously Treated Chronic Lymphocytic Leukemia 9/15/2014
OSE Pharma Release: Texopi®, A New Ray Of Hope For Lung Cancer Immunotherapy 9/15/2014
Eli Lilly and Company (LLY)'s Cyramza Met Primary Endpoint In Phase 3 Study 9/12/2014
AbbVie (ABBV)'s Phase 3 Trial Of Humira Meets Primary Endpoint 9/12/2014
Sanofi (France) (SAN.PA)'s Genzyme Corporation (GENZ) Report Positive New Data From Lemtrada Multiple Sclerosis Trial 9/12/2014
Intarcia Therapeutics, Inc. Announces Two Presentations At 50th EASD Meeting: Confirms Pivotal Phase 3 Data Announcement For ITCA 650 In Type 2 Diabetes In 4Q 9/12/2014
Detailed Results From Biogen Idec, Inc. (Massachusetts) (BIIB) And AbbVie (ABBV)’s Pivotal Phase 3 Decide Study Further Define The Efficacy And Safety Profile Of ZINBRYTA™ (Daclizumab High-Yield Process) 9/12/2014
ZS Pharma (ZSPH) To Present Data From Phase 3 Trial Of ZS-9 In Late-Breaking Session At Heart Failure Society Of America 18th Annual Scientific Meeting 9/11/2014
Mologen AG (MOLGF.PK): Initiation Of Phase 3 IMPALA Study With Immunotherapy MGN1703 In Colorectal 9/11/2014
Biogen Idec, Inc. (Massachusetts) (BIIB) Release: PLEGRIDY™ (Peginterferon Beta-1a) Two-Year Data Confirm Maintenance Of Efficacy And Safety In Multiple Sclerosis Patients 9/11/2014
Biogen Idec, Inc. (Massachusetts) (BIIB) Release: New Data From ENDORSE Show Positive Results Continued Over Five Years With TECFIDERA® (Dimethyl Fumarate) In A Wide Range Of Multiple Sclerosis Patients 9/11/2014
Thoratec Corporation (THOR) Announces Start Of Heartmate 3™ U.S. Clinical Trial 9/10/2014
Nymox Pharmaceutical (NYMX) Announces Positive Prostate Cancer 8 Month Clinical Trial Results 9/10/2014
AcelRx Pharmaceuticals (ACRX) Announces Publication Of Manuscript Analyzing Cost Of Intravenous Patient-Controlled Analgesia With Opioids 9/10/2014
Eisai Inc. (ESALF.PK) Release: Lorcaserin HCl Data To Be Presented At The American Society of Bariatric Physicians' 64th Annual Obesity & Associated Conditions Symposium 9/10/2014
SANUWAVE, Inc. Receives Information From The Data Monitoring Committee On The Dermapace Clinical Trial 9/10/2014
University of Minnesota Masonic Cancer Center Joins CEL-SCI (CVM)’s Phase 3 Head & Neck Cancer Trial 9/10/2014
GlaxoSmithKline (GSK) Takes Lead In New Wave Of Biotech Lung Drugs As Mepolizumab Performs In Phase 3 Study 9/10/2014
Evoke Pharma, Inc. Announces The Completion Of Enrollment In Its Thorough ECG Study For EVK-001 9/9/2014
PTC Therapeutics, Inc. (PTCT) Completes Enrollment Of Landmark Trial In Duchenne Muscular Dystrophy 9/9/2014
Charleston Laboratories, Inc. Announces Key Clinical Updates For Novel Drugs 9/9/2014
Spectrum Pharmaceuticals, Inc. (SPPI) Makes Decision To Advance SPI-2012, A Novel Long-Acting GCSF, To Phase 3 Due To Positive Phase 2 Results In Its Collaboration Program With Hanmi Pharmaceutical, Co., Ltd 9/9/2014
Vital Therapies, Inc. (VTI) (VTL) Announces Management Addition; Enrollment In VTI-208 Phase 3 Trial Now 75 Percent Complete 9/8/2014
Melinta Therapeutics (Formerly known as Rib-X Pharmaceuticals, Inc.) Reports On PK Profile Of A Single Oral Dose Of Delafloxacin In Support Of U.S. Phase 3 Gonorrhea Program 9/8/2014
Relypsa, Inc. (RLYP) Announces Phase 3 Patiromer Data To Be Presented In Late-Breaking Session At Heart Failure Society Of America 18th Annual Scientific Meeting 9/8/2014
Skyepharma PLC (SKYEF)’s Partner Mundipharma AG Announces Results Of Pivotal Phase III Study For Flutiform® In Paediatric Asthma 9/8/2014
Celsion Corporation (CLSN) Announces Highlights From Three Presentations Given At The International Liver Cancer Association 2014 Annual Conference 9/8/2014
Melinta Therapeutics (Formerly known as Rib-X Pharmaceuticals, Inc.) Demonstrate Delafloxacin's Potent And Rapid Antimicrobial Activity Against Neisseria Gonorrhoeae 9/8/2014
Evotec AG (EVTG.F) Announces Update On DiaPep277® 9/8/2014
Boehringer Ingelheim Pharmaceuticals, Inc. Release: New Phase 3 Study Shows Investigational Tiotropium Improves Lung Function In Adolescent Patients With Symptomatic Asthma 9/8/2014
Successful Completion Of Phase 3 Program For Teva Pharmaceutical Industries Limited (TEVA)’s Reslizumab Two More Phase Iii Studies Support The Benefits Of Reslizumab Treatment In Asthma Patients With Eosinophilia 9/8/2014
Boehringer Ingelheim Corporation Release: TONADO™ - Further Lung Function And Quality Of Life Benefits With Tiotropium + Olodaterol Respimat® FDC* In COPD 9/8/2014
Purdue Pharma L.P. Release: New Research Highlights An Investigational Single-Entity Formulation Hydrocodone Bitartrate Extended-Release Tablet At PAINWeek 9/8/2014
Sosei Group Corporation Announces Positive Results For Ultibro® And Seebri® Presented At ERS 2014, And Promotion Agreement With Pfizer Inc. (PFE) In The UK 9/8/2014
AcelRx Pharmaceuticals (ACRX) Announces Publication Of Sufentanil Sublingual Tablet System Vs. Intravenous Patient-Controlled Analgesia With Morphine For Postoperative Pain Study Results 9/5/2014
Eli Lilly and Company (LLY)'s Diabetes Drug Trumps Sanofi (France) (SAN.PA)'s In Phase 3 Trials 9/5/2014
Exelixis, Inc. (EXEL) Chops 70 Percent Of Workforce After Prostate Drug Cabozantinib Fails Pivotal Study 9/4/2014
Novartis AG (NVS)'s New Heart Drug Cuts Cardiovascular Death Risk By 20 Percent; "Most Exciting Ever" Med Points To Huge Sales 9/4/2014
Flexion Therapeutics (FLXN) To Start FX006 Phase 3 Pivotal Trial In 2014; Following FDA Meeting, Development Plan Advanced By One Year 9/4/2014
Celgene Corporation (CELG) Release: Phase III FIRST™ (MM-020/IFM 07-01) Trial Of REVLIMID® (lenalidomide) Plus Dexamethasone In Newly Diagnosed Multiple Myeloma Patients Who Are Not Candidates For Stem Cell Transplant Published In New England Journal Of Medicine 9/4/2014
FDA Grants Fast Track Designation To Aradigm Corporation (ARDM)’s Pulmaquin For Non-Cystic Fibrosis Bronchiectasis 9/4/2014
Final Landmark Trial Confirms Efficacy Of Sanofi (France) (SAN.PA)'s Dengue Vaccine 9/3/2014
San Diego's ACADIA Pharmaceuticals, Inc. (ACAD) Wins FDA Breakthrough Therapy Designation For NUPLAZID™ 9/3/2014
RedHill Biopharma Ltd. (RDHL) Initiates Phase 3 Study Of RHB-102 For Gastroenteritis 9/3/2014
CEL-SCI (CVM) Enrolls 20 Patients In August In Its Phase 3 Immunotherapy Head And Neck Cancer Trial 9/3/2014
Celsion Corporation (CLSN) Announces Enrollment Of First Patient In Global Phase 3 OPTIMA Study Of Thermodox® In Primary Liver Cancer 9/3/2014
Aerie Pharmaceuticals, Inc. (AERI) Initiates Phase 3 Safety-Only Registration Trial in Canada Of Rhopressa™ In Patients With Glaucoma 9/3/2014
TetraPhase Pharmaceuticals Announces Positive Oral Dosing Data From Lead-in of IGNITE 2 Phase 3 Trial Of Eravacycline In cUTI Support Advancement To Pivotal Portion 9/3/2014
Daiichi Sankyo Company, Limited Release: Subgroup Analysis of ENGAGE AF-TIMI 48 Explores the Relationship Between Edoxaban Dose, Concentration, Anti-Factor Xa Activity and Outcomes 9/3/2014
Early Phase 3 Data Suggest Sanofi (France) (SAN.PA), Regeneron Pharmaceuticals, Inc. (REGN) Drug May Halve Heart Risk 9/3/2014
Hatchtech Announces Successful Phase 3 Study Results For Xeglyze™ Lotion 9/2/2014
Macrocure (MCUR) Completes Enrollment In Pivotal Phase 3 Clinical Trial Of Curexcell In Diabetic Foot Ulcers 9/2/2014
Sophiris Bio Inc. (SPHS) Reports Completion Of Enrollment In The "PLUS-1" Phase 3 Trial Of PRX302 For Benign Prostatic Hyperplasia 9/2/2014
Teva Pharmaceutical Industries Limited (TEVA)’s Reslizumab Delivers Clinically And Statistically Significant Reduction In Asthma Exacerbations In Two Pivotal Phase 3 Studies 9/2/2014
XBiotech USA, Inc. Halts Cancer Study On Positive Phase 3 Results 9/2/2014
Ampio Pharmaceuticals, Inc. (AMPE) Release: Update On The Phase 3 Multicenter, Double-Blind STEP Study Of Ampion™ For Osteoarthritis Of The Knee 9/2/2014
Birken Announces Positive Results Of Phase 3 Trials With Oleogel-S10 For Accelerated Wound Healing In Patients With Partial Thickness Wounds 9/2/2014
Amgen (AMGN)'s Cholesterol Lowering Drug Succeeds In Phase 3 Trial 8/29/2014
Isis Pharmaceuticals, Inc. (ISIS) Initiates Phase 3 Study Of ISIS-APOCIII Rx In Patients With FCS 8/28/2014
FDA Grants Amgen (AMGN) Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 8/27/2014
RedHill Biopharma Ltd. (RDHL) Provides Update On Expansion Of Ongoing RHB-105 Phase 3 Study, Targeting Broadened H. Pylori Indication Authorized By FDA 8/27/2014
ZS Pharma (ZSPH) To Present Late-Breaking Abstract Data From Phase 3 Trial Of ZS-9 In State Of The Art And Featured Research Session Oral Presentation At European Society of Cardiology Congress 8/26/2014
The Neurocritical Care Society Announces Trial Results & New Guidelines At Their 2014 Annual Meeting 8/26/2014
Regado Biosciences, Inc. (RGDO) Permanently Halts Enrollment In Lead Drug Trial 8/26/2014
Regeneron Pharmaceuticals, Inc. (REGN) And Sanofi (France) (SAN.PA) To Present Results From Four Phase 3 Alirocumab Trials In Hot Line Session At ESC Congress 2014 8/25/2014
La Jolla Pharmaceutical Company (LJPC) Announces First Patient Enrolled In Clinical Trial Of LJPC-501 In Hepatorenal Syndrome 8/25/2014
Adocia Launches Phase III Clinical Study In India Of Treatment For Diabetic Foot Ulcer 8/25/2014
Janssen Research & Development Release: Data on XARELTO® At ESC Congress 2014 Hot Line Session Premieres First Prospective Study Of A Factor Xa Inhibitor In Elective Cardioversion 8/25/2014
Update: OncoGenex Pharmaceuticals Inc. (OGXI) Phase 3 ENSPIRIT Trial Continuing As Planned 8/22/2014
Eli Lilly and Company (LLY)'s Psoriasis Drug Ixekizumab Succeeds In Late-Stage Studies 8/21/2014
Long-Acting Version Of Baxter International, Inc. (BAX)'s Hemophilia A Drug BAX 855 Succeeds In Study 8/21/2014
Amicus Therapeutics, Inc. (FOLD) Rockets On Positive Phase 3 Study Data For Rare Disease Drug 8/21/2014
Good News For Amgen (AMGN) As Parathyroid Drug AMG 416 Succeeds In Phase 3 Study 8/20/2014
CEL-SCI (CVM) Expands Its Global Phase 3 Immunotherapy Head And Neck Cancer Trial Into Centre Hospitalier Universitaire De Quebec In Canada 8/19/2014
Actavis (ACT) Reports Positive Top-Line Data From Two Ceftazidime-Avibactam Late-Stage Trials 8/19/2014
Auspex Pharmaceuticals Completes Enrollment In Phase 3 Registration Clinical Trial Of SD-809 In Chorea Associated With Huntington's Disease 8/18/2014
Amgen (AMGN) Drops After Hours On Failed Phase 3 Multiple Myeloma Trial 8/18/2014
Supernus Pharmaceuticals (SUPN) Snags FDA Fast Track Designation For ADHD Drug SPN-810 8/15/2014
FDA Accepts CorMedix (CRMD) Pivotal Phase 3 Study Protocol 8/15/2014
AstraZeneca PLC (AZN) Starts Late-Stage Asthma Drug Trial 8/14/2014
Taxus Cardium (CRXM) Announces Biological And Clinical Advances In Angiogenic Gene Therapy For Heart Disease In Journal Of Cardiovascular Pharmacology 8/13/2014
Cardium Therapeutics, Inc. (CXM) Announces Review In Journal Of Cardiovascular Pharmacology Finds Gene Therapy For Subset Of Heart Disease Patients 'Highly Warranted' 8/13/2014
Mologen AG (MOLGF.PK): Preparation And Launch Of New Studies Characterized The First Half-Year 2014 8/13/2014
AstraZeneca PLC (AZN) Gets A Pipeline Boost From Good Phase 3 Gout Drug Results 8/13/2014
Northwest Biotherapeutics (NWBO) Corrects Ongoing False Claims, Phase 3 Dcvax®-L Trial Is Alive And Well 8/13/2014
Cempra Initiates Phase 3 Clinical Trial In Patients With Uncomplicated Gonorrhea Infection 8/12/2014
Juventas Therapeutics, Inc. Completes Enrollment Of Phase I/II RETRO-HF Trial And Demonstrates Safety For Retrograde Infusion Of JVS-100 In Patients With Heart Failure 8/12/2014
Cortendo AB: First Patient Enrolled Into Normocort Phase 3 SONICS Trial Following A Successful EU Investigator Meeting 8/12/2014
Salix Pharmaceuticals, Ltd. (SLXP) Announces Important Topline Results For Microbiome, Culture & Susceptibility, And Key Secondary Efficacy Results For TARGET 3, Rifaximin IBS-D Repeat Treatment Study 8/12/2014
Opko Health, Inc. Release: Rayaldee Phase 3 Trial Meets Primary Endpoints 8/12/2014
Tolero Pharmaceuticals And Eutropics Pharmaceuticals Announce Data Demonstrating Clinical Utility Of Praedicare Dx In Guiding New Drug Treatment Of CLL Patients 8/12/2014
Evoke Pharma, Inc. Announces Initiation Of A Thorough ECG (QT) Study For EVK-001 8/12/2014
Novartis AG (NVS) To Tout Heart Failure Data At European Society of Cardiology Congress 2014 8/12/2014
Genmab A/S (GEN.CO) Announces New Phase 3 Study Of Daratumumab In Front Line Multiple Myeloma 8/11/2014
Catalyst Pharmaceutical Partners, Inc. (CPRX) Provides Updates On Progress Of Phase 3 Firdapse Study In Patients With Lambert-Eaton Myasthenic Syndrome (LEMS) 8/11/2014
Northwest Biotherapeutics (NWBO) Provides Update About Phase 3 Dcvax®-L Trial For Gbm And "Information Arm" Compassionate Use Patients 8/11/2014
Northwest Biotherapeutics (NWBO) Obtains Approvals For Enhancements Of Phase 3 Trial Of Dcvax®-L For Gbm Brain Cancer 8/11/2014
Avillion Announces Dosing Of First Patients In Phase 3 BFORE Trial To Assess BOSULIF® (bosutinib) As First-Line Treatment For Patients With Chronic Myelogenous Leukemia 8/11/2014
CTI BioPharma Granted Fast Track FDA Status For Pacritinib 8/7/2014
Collegium Pharmaceutical, Inc. Announces Positive Top-Line Data From Phase III Study of Oxycodone DETERx®, Its Abuse-Deterrent, Extended-Release Product For Chronic Pain 8/7/2014
New Data Shows High Efficacy For Can-Fite BioPharma (CFBI)'s CF101 In Rheumatoid Arthritis And Psoriasis Patients 8/6/2014
BioDelivery Sciences International (BDSI) Provides Update On Ongoing Phase 3 Pivotal Trial For Clonidine Topical Gel For Painful Diabetic Neuropathy 8/6/2014
Hope Builds For New Novartis AG (NVS) Heart Failure Drug LCZ696 8/5/2014
Concordia Healthcare Corp (CXR.TO) Initiates Phase 3 Bile Duct Cancer Trial Using Photodynamic Therapy With PHOTOFRIN® 8/5/2014
Amgen (AMGN) Drug Kyprolis Helped Patients Live 8.7 Months Longer In Late-Stage Trial 8/5/2014
XBiotech USA, Inc. Enrolls First Patient In Phase III European Registration Study Using Xilonix™ For Treatment Of Colorectal Cancer 8/4/2014
Mologen AG (MOLGF.PK): First Approvals For Phase III IMPALA Colorectal Cancer Study 8/4/2014
Isis Pharmaceuticals, Inc. (ISIS) Initiates Phase 3 Study Of ISIS-SMN Rx In Infants With Spinal Muscular Atrophy 8/1/2014
CEL-SCI (CVM) Achieves Milestone In July With Total Of 232 Patients Enrolled To Date In Its Phase 3 Head And Neck Cancer Trial 8/1/2014
Genmab A/S (GEN.CO), GlaxoSmithKline (GSK)'s Ofatumumab Meets Primary Endpoint In Late-Stage Study 8/1/2014
New Data On Chimerix, Inc. (CMRX)'s brincidofovir Supports Safety And Antiviral Activity Against Multiple Life-Threatening DNA Viruses In Organ Transplant Recipients 7/31/2014
Regeneron Pharmaceuticals, Inc. (REGN), Sanofi (France) (SAN.PA) Drug Alirocumab Cuts Cholesterol In Nine Late-Stage Trials 7/30/2014
Eisai Inc. (ESALF.PK) And Arena Pharmaceuticals, Inc. (ARNA) Announce Publication Of Post-Hoc Analyses Of Lorcaserin Phase 3 Clinical Trial Results In Obesity 7/30/2014
Alkermes plc (ALKS) Announces Initiation Of FORWARD-5 Clinical Study Of ALKS 5461 For Treatment Of Major Depressive Disorder 7/30/2014
Bioniche Life Sciences Inc. (BNC) Announces Submission Of Orphan Drug Designation Application For MCNA In The United States 7/29/2014
Incyte Corporation (INCY)'s Jakafi Fails to Provide RELIEF In Phase 3 Trial 7/28/2014
Celsion Corporation (CLSN) Shows Off Positive ThermoDox® Data In Primary Liver Cancer Patients 7/28/2014
TetraPhase Pharmaceuticals Completes Enrollment Of IGNITE 1 Eravacycline Phase 3 Clinical Trial in Complicated Intra-abdominal Infections 7/28/2014
Incyte Corporation (INCY) Release: Jakafi® (ruxolitinib) Product Label Expanded To Include Overall Survival Data And Additional Safety And Dosing Information 7/28/2014
Puma Biotechnology (PBYI) Shares Soar On Breast Cancer Drug Results 7/28/2014
Amgen (AMGN), Bayer HealthCare (BAY)'s Nexavar Fails Late-Stage Breast Cancer Study 7/25/2014
Kidney Dialysis Drug Phase 3 Data Boost Keryx Biopharmaceuticals (KERX)'s Hopes For U.S. Approval 7/25/2014
DermaTools Biotech GmbH Release: Clinical Development Of Wound Healing Drug Dermapro® Progressing On Schedule In Europe 7/25/2014
Bayer HealthCare AG (BAY) Release: Phase 3 Investigational Trial Of Azelaic Acid 15% Foam Meets Both Co-Primary Endpoints In Subjects With Papulopustular Rosacea 7/24/2014
Merck & Co., Inc. (MRK) Initiates Phase 3 Study Of Letermovir, An Investigational Antiviral For Prevention Of Cytomegalovirus (CMV) Infection In High-Risk Bone Marrow Transplant Patients 7/24/2014
rEVO Biologics Announces Enrollment Of First Patient In Phase 3 Trial Of Atryn® To Treat Early Onset Preeclampsia (PRESERVE-1) 7/24/2014
Aerie Pharmaceuticals, Inc. (AERI) Receives Health Canada "No Objection Letter" To Commence Phase 3 Registration Trial Of Rhopressatm In Patients With Glaucoma In Canada 7/24/2014
Pfizer Inc. (PFE) Backs Out of Funding Puma Biotechnology (PBYI) Cancer Drug Trials 7/24/2014
CEL-SCI (CVM) Has Been Cleared to Begin Patient Enrollment 7/23/2014
ViiV Healthcare: HIV Combo Therapy Candidate Fails Phase 3 7/23/2014
Major Advance In UCB Pipeline: Positive Topline Phase 3 Results For brivaracetam In Epilepsy Patients With Partial-Onset Seizures 7/23/2014
Synta Pharmaceuticals (SNTA) Announces Advancement Of Ganetespib Into Phase 3 Extension Of AML LI-1 Study For Patients With AML And High-Risk MDS 7/22/2014
Nymox Pharmaceutical (NYMX) Announces Positive Efficacy Results In Phase 3 Repeat Injection Trial Of NX-1207 For BPH 7/22/2014
Argos Therapeutics, Inc. (ARGS) Presents Data Showing The Impact Of HIV Antigen Sequence Divergence On Durable Viral Control Following Treatment With Autologous Immune Therapy 7/22/2014
Antares Pharma, Inc. (ATRS) Announces First Patient Dosed in Phase 3 QuickShot Study Evaluating Testosterone-Deficient Adult Males 7/22/2014
Enrollment Commences In NeuroSigma, Inc.-Sponsored Pediatric Clinical Trial For The Treatment Of Lennox-Gastaut Syndrome 7/22/2014
PSI CRO Launches A Global Phase 3 Rare Disease Trial 7/22/2014
Amgen (AMGN) Thyroid Drug AMG 416 Succeeds In Late Stage Kidney Patient Trial 7/21/2014
Proteon Therapeutics, Inc. Initiates Phase 3 Clinical Study Of PRT-201 In Patients With Chronic Kidney Disease Undergoing Surgical Placement Of An Arteriovenous Fistula For Hemodialysis 7/21/2014
Braeburn Pharmaceuticals Enrolls First Patients In Late-Stage Clinical Study Of Probuphine® For Opioid Dependence 7/21/2014
Dipexium Pharmaceuticals (DPRX) Initiates Second Of Two Pivotal Phase 3 Clinical Trials Of Locilex® In Patients With Mild Infections Of Diabetic Foot Ulcers 7/21/2014
InterMune, Inc. (ITMN) Grabs FDA Breakthough Therapy Designation For IPF Drug Pirfenidone 7/18/2014
Genmab A/S (GEN.CO) Announces Phase 3 Study Of Daratumumab In Front Line Multiple Myeloma 7/18/2014
Regeneron Pharmaceuticals, Inc. (REGN) Release: Two-Year Results From Phase 3 VIVID-DME Trial Of EYLEA® (aflibercept) Injection For The Treatment Of Diabetic Macular Edema Show Sustained Improvement In Vision 7/18/2014
Agile Therapeutics, Inc. Announces Allowance Of Additional Patent Claims For Skinfusion® 7/18/2014
Auspex Pharmaceuticals Initiates Pivotal Phase 2/3 Clinical Trial For SD-809 In Tardive Dyskinesia 7/17/2014
CEL-SCI (CVM) Expands Its Phase 3 Head And Neck Cancer Trial Into Sri Lanka 7/17/2014
Dipexium Pharmaceuticals (DPRX) Initiates Pivotal Phase 3 Clinical Trial Of Locilex® In Patients With Mild Infections Of Diabetic Foot Ulcers 7/17/2014
New England Journal Of Medicine Publishes Ipsen (IPN.PA)’s Somatuline® CLARINET® Phase III Results In Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors 7/17/2014
TauRx Therapeutics Achieves Enrollment Target In The First Of Its Two Phase III Clinical Trials Of LMTX™ In Alzheimer's Disease 7/17/2014
GlaxoSmithKline (GSK), Theravance, Inc. (THRX) Begin Pivotal Phase 3 Trial For Triple Combination Treatment 7/16/2014
Boehringer Ingelheim Corporation's Investigational Therapy Nintedanib Receives FDA Breakthrough Therapy Designation 7/16/2014
Pfizer Inc. (PFE) Hemophilia B Treatment Regimen Meets Endpoint In Phase 3 Trial 7/16/2014
Rigel Pharmaceuticals, Inc. (RIGL) Initiates Phase 3 Studies Of Fostamatinib In ITP 7/16/2014
Coherus Biosciences Announces Initiation Of Phase 3 Trial Of CHS-0214 (Investigational Etanercept Biosimilar) In Chronic Plaque Psoriasis (RaPsOdy) 7/16/2014
AVANIR Pharmaceuticals (AVNR) Announces Presentation Of Positive Early Results From Prism II Study 7/16/2014
Exelixis, Inc. (EXEL) And Genentech (RHHBY)'s Melanoma Combination Drug Meets Main Goal In Phase 3 Study 7/15/2014
ZS Pharma (ZSPH) Completes Patient Enrollment In ZS004, Its Second Phase 3 Study Of ZS-9 In Patients With Hyperkalemia 7/15/2014
Eli Lilly and Company (LLY) Release: New Data Shows Cognitive Impairment Precedes And Predicts Subsequent Functional Impairment In Patients With Mild Alzheimer's Disease 7/15/2014
Nymox Pharmaceutical (NYMX) Announces Completion Of Enrollment For Second BPH Re-Injection Study 7/15/2014
Aerie Pharmaceuticals, Inc. (AERI) Initiates Phase 3 Registration Trials of Rhopressa™, Novel Triple-Action Product To Lower Intraocular Pressure In Patients With Glaucoma 7/15/2014
Neos Therapeutics Announces Positive Phase 3 Study Results For Its Methylphenidate Extended-Release (XR) Oral Disintegrating Tablet (ODT) In ADHD Patients 7/15/2014
FDA Green Lights Starpharma Holdings Ltd's VivaGel Trial Design 7/14/2014